SYRE

Spyre Therapeutics Stock Analysis

AI Rating

Good
  • Quality1/10
  • Growth↑ 7/10
  • Value↑ 6/10
Spyre Therapeutics sales and earnings growth
SYRE Growth
Good
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↑ 30.26%
  • FCF Y/Y↓ -9.28%
Spyre Therapeutics gross and profit margin trends
SYRE Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↓ 549.54%
Spyre Therapeutics net debt vs free cash flow
SYRE Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Spyre Therapeutics stock volatility is higher than the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks